Is Denali Therapeutics (DNLI) Undervalued As Its Share Price Pullback Tests Fair Value?

Denali Therapeutics (DNLI) has pulled back sharply, with the share price down about 15% over the past month and 27% in the past 3 months. This decline has drawn fresh attention to its valuation. Short term momentum for Denali Therapeutics has clearly cooled, with the 7 day share price return down 9.1% and the 3 month share price return down 27.3%, even though the year to date share price return is still up 14.8% and the 1 year total shareholder return is 15.5%. This suggests that recent...